AU1125192A - Fusion proteins for prodrug activation, the preparation and use thereof - Google Patents

Fusion proteins for prodrug activation, the preparation and use thereof

Info

Publication number
AU1125192A
AU1125192A AU11251/92A AU1125192A AU1125192A AU 1125192 A AU1125192 A AU 1125192A AU 11251/92 A AU11251/92 A AU 11251/92A AU 1125192 A AU1125192 A AU 1125192A AU 1125192 A AU1125192 A AU 1125192A
Authority
AU
Australia
Prior art keywords
beta
hutumab
gluc
fusion proteins
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU11251/92A
Other versions
AU660445B2 (en
Inventor
Klaus Boblet
Jorg Czech
Dieter Hoffmann
Cenek Kolar
Hans-Harald Sedlacek
Gerhard Seemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of AU1125192A publication Critical patent/AU1125192A/en
Application granted granted Critical
Publication of AU660445B2 publication Critical patent/AU660445B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to fusion proteins for prodrug activation of the general formula huTuMAb-L- beta -gluc, where huTuMAb is a humanised or human tumour-specific monoclonal antibody or a fragment thereof, L is a linker and beta -gluc comprises human beta -glucuronidase. These fusion proteins are prepared by genetic manipulation. huTuMAb ensures specific location of tumours, L connects huTuMAb to beta -gluc in a way which does not hinder the specific properties of the two fusion partners, and beta -gluc activates a suitable prodrug compound by elimination of glucuronic acid, and owing to the humanised or human fusion partner a virtually autologous system is available for use in humans.
AU11251/92A 1991-02-28 1992-02-27 Fusion proteins for prodrug activation, the preparation and use thereof Expired AU660445B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4106389A DE4106389A1 (en) 1991-02-28 1991-02-28 FUSION PROTEINS FOR PRODRUG ACTIVATION, THEIR PRODUCTION AND USE
DE4106389 1991-02-28

Publications (2)

Publication Number Publication Date
AU1125192A true AU1125192A (en) 1993-01-28
AU660445B2 AU660445B2 (en) 1995-06-29

Family

ID=6426148

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11251/92A Expired AU660445B2 (en) 1991-02-28 1992-02-27 Fusion proteins for prodrug activation, the preparation and use thereof

Country Status (12)

Country Link
EP (1) EP0501215B1 (en)
JP (1) JP3524933B2 (en)
KR (1) KR100249576B1 (en)
AT (1) ATE193326T1 (en)
AU (1) AU660445B2 (en)
CA (1) CA2062047C (en)
DE (2) DE4106389A1 (en)
DK (1) DK0501215T3 (en)
ES (1) ES2149159T3 (en)
GR (1) GR3033708T3 (en)
IE (1) IE920630A1 (en)
PT (1) PT501215E (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666029B2 (en) * 1992-08-05 1996-01-25 Behringwerke Aktiengesellschaft Granulocyte-binding antibody fragments, their preparation and use
US5876691A (en) * 1993-12-03 1999-03-02 Cancer Research Campaign Technology Limited Antibody against carcionembryonic antigen (CEA)
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4233152A1 (en) * 1992-10-02 1994-04-07 Behringwerke Ag Antibody-enzyme conjugates for prodrug activation
DE4314556A1 (en) * 1993-05-04 1994-11-10 Behringwerke Ag Modified antibody-enzyme conjugates and fusion proteins and their use in tumor-selective therapy
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE19513676A1 (en) 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli
DK0795334T3 (en) * 1996-03-12 2006-06-06 Sanofi Aventis Deutschland New prodrugs for the treatment of tumors and inflammatory diseases
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
ATE499115T1 (en) * 1998-09-18 2011-03-15 Immunomedics Inc ANTIBODIES REFERRED ENZYME PRODRUG THERAPY WITH GLUCURONIDASE
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US7834258B2 (en) * 2003-06-30 2010-11-16 Mu-Hyeon Choe Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
CR20190309A (en) 2017-01-03 2019-08-21 Hoffmann La Roche Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT80662B (en) * 1984-06-20 1986-12-09 Sanofi Sa Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
FR2591895B1 (en) * 1985-12-20 1988-08-26 Sanofi Sa LONG-LASTING IN VIVO IMMUNOTOXINS HAVING MODIFIED RICIN A CHAIN ON ITS POLYSACCHARIDE PATTERNS
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
DE3825615A1 (en) * 1988-07-28 1990-02-01 Behringwerke Ag ANTIGENT CONSTRUCTS OF "MAJOR HISTOCOMPATIBILITY COMPLEX" CLASS I ANTIGENS WITH SPECIFIC CARRIER MOLECULES, THEIR PRODUCTION AND USE
EP0454783B1 (en) * 1989-01-23 1995-06-07 Akzo Nobel N.V. Site specific in-vivo activation of therapeutic drugs
DE3909799A1 (en) * 1989-03-24 1990-09-27 Behringwerke Ag MONOCLONAL ANTIBODIES (MAK) AGAINST TUMOR ASSOCIATED ANTIGENS, THEIR PRODUCTION AND USE
DE68928946T2 (en) * 1989-12-11 1999-10-21 Immunomedics, Inc. METHOD FOR DETECTING DIAGNOSTIC OR THERAPEUTIC AGENTS BY ANTIBODIES
DE4002888A1 (en) * 1990-02-01 1991-08-08 Behringwerke Ag ANTHRACYCLIN-GLYCOSYL PRODRUGS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN COMBINATION WITH FUNCTIONALIZED TUMOR-SPECIFIC ENZYME CONJUGATES

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666029B2 (en) * 1992-08-05 1996-01-25 Behringwerke Aktiengesellschaft Granulocyte-binding antibody fragments, their preparation and use
US5876691A (en) * 1993-12-03 1999-03-02 Cancer Research Campaign Technology Limited Antibody against carcionembryonic antigen (CEA)
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US7626011B2 (en) 2002-07-01 2009-12-01 Cancer Research Technology Limited Antibodies against tumor surface antigens

Also Published As

Publication number Publication date
EP0501215A3 (en) 1993-08-11
ATE193326T1 (en) 2000-06-15
JP3524933B2 (en) 2004-05-10
PT501215E (en) 2000-10-31
KR100249576B1 (en) 2000-03-15
DE59209839D1 (en) 2000-06-29
GR3033708T3 (en) 2000-10-31
EP0501215B1 (en) 2000-05-24
CA2062047C (en) 2007-12-18
JPH07179500A (en) 1995-07-18
CA2062047A1 (en) 1992-08-29
DK0501215T3 (en) 2000-09-18
DE4106389A1 (en) 1992-09-03
AU660445B2 (en) 1995-06-29
ES2149159T3 (en) 2000-11-01
IE920630A1 (en) 1992-09-09
EP0501215A2 (en) 1992-09-02

Similar Documents

Publication Publication Date Title
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
AU1125192A (en) Fusion proteins for prodrug activation, the preparation and use thereof
HK1012841A1 (en) Pharmaceutical composition for the treatment or prevention of amalignant tumor
ES2146212T3 (en) UNION SPECIFIC TRIVALENT ANTIGENS UNION PROTEINS.
EP0683234A4 (en) ANTIBODY AGAINST -g(b)-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF.
AU2324488A (en) Modular assembly of antibody genes, antibodies prepared thereby and use
DE60025832D1 (en) MULTIPLE CYTOKINE ANTIBODIES COMPLEX
EP1329459A3 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
HK1023513A1 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
AU1885197A (en) Antibody variants
AU3076601A (en) Chemically-programmable immunity
ATE304371T1 (en) USE OF STAPHYLOCOCCUS ENTEROTOXIN HOMOLOGUE FOR CANCER THERAPY
AU6171894A (en) Preparation of photoprotein conjugates and methods of use thereof
DE69317886D1 (en) NEW PROPOXYPHENE DERIVATIVES AND THEIR PROTEIN AND POLYPEPTIDE LABELS AND CONJUGATES
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
IL187595A (en) Pharmaceutical composition comprising a monoclonal antitumor antibody and its manufacture
AU4441393A (en) Granulocyte-binding antibody fragments, their preparation and use
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
CA2107329A1 (en) Anti-Human Immunodeficiency Virus Recombinant Antibodies
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
PT998493E (en) TOXIN EPITHOPS SIMILAR TO SHIGELLA AND ITS USE AS VACCINES AND DIAGNOSTICS
AU2687992A (en) Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof